Patents by Inventor Christophe Bonny

Christophe Bonny has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240327471
    Abstract: The present invention relates to polypeptides, which are capable of inducing and/or enhancing secretion of IL-10 from human cells. Accordingly, the present invention provides polypeptides, which stimulate IL-10 release from human immune cells. The present invention also relates to nucleic acids encoding such polypeptide, cells expressing such polypeptide, respective pharmaceutical compositions and uses thereof.
    Type: Application
    Filed: July 26, 2022
    Publication date: October 3, 2024
    Inventors: Christophe BONNY, Antonietta CULTRONE, Helene PFISTER
  • Publication number: 20240293520
    Abstract: The present invention relates to antigen-based immunotherapy, in particular cancer immunotherapy. In particular, the present invention provides antigenic peptides, which are distinct from, but have amino acid similarity to, fragments of human tumor antigens. The present invention further provides immunogenic compounds, nanoparticles, cells and pharmaceutical compositions comprising such antigenic peptides and nucleic acids encoding such antigenic peptides.
    Type: Application
    Filed: May 3, 2024
    Publication date: September 5, 2024
    Inventors: Laurent CHENE, Christophe BONNY, Francesco STROZZI
  • Patent number: 12016910
    Abstract: The present invention relates to antigen-based immunotherapy, in particular cancer immunotherapy. In particular, the present invention provides antigenic peptides, which are distinct from, but have amino acid similarity to, fragments of human tumor antigens. The present invention further provides immunogenic compounds, nanoparticles, cells and pharmaceutical compositions comprising such antigenic peptides and nucleic acids encoding such antigenic peptides.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: June 25, 2024
    Assignee: ENTEROME S.A.
    Inventors: Laurent Chene, Christophe Bonny, Francesco Strozzi
  • Publication number: 20240075117
    Abstract: The present invention relates to cancer immunotherapy, in particular to sequence variants of tumor-related antigenic epitope sequences. Namely, the present invention provides a method for identification of microbiota sequence variants of tumor-related antigenic epitope sequences. Such microbiota sequence variants are useful for the preparation of anticancer medicaments, since they differ from self-antigens and, thus, they may elicit a strong immune response. Accordingly, medicaments comprising microbiota sequence variants, methods of preparing such medicaments and uses of such medicaments are provided.
    Type: Application
    Filed: June 26, 2023
    Publication date: March 7, 2024
    Inventors: Laurent CHENE, Alessandra Cervino, Francesco Strozzi, Celia Mendez, Christophe Bonny
  • Patent number: 11898210
    Abstract: The present invention relates to an in vitro method for identifying subjects hosting high amounts of Fim H expressing proteobacteria in their gut, said method comprising the step of detecting the expression of the fimH gene in a stool sample of said subjects.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: February 13, 2024
    Assignee: ENTEROME
    Inventors: Alessandra Cervino, Christophe Bonny, Jonathan Plassais
  • Publication number: 20230257423
    Abstract: The present disclosure relates to novel pharmaceutical compositions comprising recombinantly engineered probiotic bacteria that can be used, inter alia, in the treatment of gastrointestinal inflammatory diseases and epithelial barrier function disorders. The probiotic bacteria preferably contain a nucleic acid encoding the heterodimeric protein of SEQ ID NO:1 and 2, or homologous sequences thereof sharing at least 80% identity with said sequences. In some embodiments, the pharmaceutical compositions described herein have particular application in the treatment or prevention of disease states associated with abnormally permeable epithelial barriers as well as inflammatory bowel diseases or disorders.
    Type: Application
    Filed: January 22, 2021
    Publication date: August 17, 2023
    Inventors: Malgorzata NEPELSKA, Joel DORE, Herve BLOTTIERE, Antonella CULTRONE, Christophe BONNY
  • Patent number: 11712465
    Abstract: The present invention relates to cancer immunotherapy, in particular to sequence variants of tumor-related antigenic epitope sequences. Namely, the present invention provides a method for identification of microbiota sequence variants of tumor-related antigenic epitope sequences. Such microbiota sequence variants are useful for the preparation of anticancer medicaments, since they differ from self-antigens and, thus, they may elicit a strong immune response. Accordingly, medicaments comprising microbiota sequence variants, methods of preparing such medicaments and uses of such medicaments are provided.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: August 1, 2023
    Assignee: ENTEROME S.A.
    Inventors: Laurent Chene, Alessandra Cervino, Francesco Strozzi, Celia Mendez, Christophe Bonny
  • Publication number: 20230221331
    Abstract: The present invention relates to the treatment of diseases relating to proteins of the human microbiome metasecretome and, thus, to microbiome interactions, especially microbiome-host interactions. In particular the present invention relates to a method for identification of secreted peptides and proteins of the human microbiome. The present invention also relates to methods for generating a database of human microbiome metasecretome protein sequences. Furthermore, the present invention relates to a method for preparing a protein of the human microbiome metasecretome as well as to the use of such proteins in medicine.
    Type: Application
    Filed: January 22, 2021
    Publication date: July 13, 2023
    Inventors: Laurent CHENE, Francesco STROZZI, Christophe BONNY
  • Publication number: 20230068615
    Abstract: The present invention relates to microbiota-derived proteins, which are capable of inducing and/or enhancing secretion of IL-10 from human cells. Accordingly, the present invention provides microbial proteins, and fragments and sequence variants thereof, which stimulate IL-10 release from human immune cells. The present invention also relates to nucleic acids encoding such proteins, cells expressing such proteins, respective pharmaceutical compositions and uses thereof.
    Type: Application
    Filed: January 22, 2021
    Publication date: March 2, 2023
    Applicant: ENTEROME S.A.
    Inventors: Antoinetta CULTRONE, Laurent CHENE, Francesco STROZZI, Christophe BONNY
  • Publication number: 20210207127
    Abstract: The present invention provides methods of selecting a target for a ligand, wherein said ligand comprises a polypeptide comprising at least three reactive groups, separated by at least two loop sequences, and a molecular scaffold which forms covalent bonds with the reactive groups of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold. The present invention also provides said targets, said ligands and methods for using and manufacturing such.
    Type: Application
    Filed: May 29, 2019
    Publication date: July 8, 2021
    Inventors: Liuhong CHEN, Christophe BONNY
  • Publication number: 20210113678
    Abstract: The present invention relates to antigen-based immunotherapy, in particular cancer immunotherapy. In particular, the present invention provides antigenic peptides, which are distinct from, but have amino acid similarity to, fragments of human tumor antigens. The present invention further provides immunogenic compounds, nanoparticles, cells and pharmaceutical compositions comprising such antigenic peptides and nucleic acids encoding such antigenic peptides.
    Type: Application
    Filed: April 11, 2019
    Publication date: April 22, 2021
    Inventors: Laurent CHENE, Christophe BONNY, Francesco STROZZI
  • Publication number: 20210106652
    Abstract: The present invention relates to antigen-based immunotherapy targeting interleukin 13 receptor alpha 2 (I LI 3RA2) for prevention and/or treatment of fibrosis, an autoimmune disease and/or an inflammatory disease. In particular, the present invention provides the use of a (poly)peptide comprising an epitope of IL13RA2 or a sequence variant thereof for prevention and/or treatment of fibrosis, an autoimmune disease and/or an inflammatory disease. Moreover, the present invention also provides an immunogenic compound, a nanoparticle and a pharmaceutical composition comprising such a (poly)peptide and a nucleic acid encoding such a (poly)peptide for use in prevention and/or treatment of fibrosis, an autoimmune disease and/or an inflammatory disease.
    Type: Application
    Filed: April 11, 2019
    Publication date: April 15, 2021
    Inventors: Laurent CHENE, Christophe BONNY, Francesco STROZZI
  • Publication number: 20200277655
    Abstract: The present invention relates to an in vitro method for identifying subjects hosting high amounts of Fim H expressing proteobacteria in their gut, said method comprising the step of detecting the expression of the fimH gene in a stool sample of said subjects.
    Type: Application
    Filed: October 16, 2018
    Publication date: September 3, 2020
    Inventors: Alessandra CERVINO, Christophe BONNY, Jonathan PLASSAIS
  • Publication number: 20200256877
    Abstract: The present invention relates to cancer immunotherapy, in particular to sequence variants of tumor-related antigenic epitope sequences. Namely, the present invention provides a method for identification of microbiota sequence variants of tumor-related antigenic epitope sequences. Such microbiota sequence variants are useful for the preparation of anticancer medicaments, since they differ from self-antigens and, thus, they may elicit a strong immune response. Accordingly, medicaments comprising microbiota sequence variants, methods of preparing such medicaments and uses of such medicaments are provided.
    Type: Application
    Filed: October 9, 2018
    Publication date: August 13, 2020
    Inventors: Laurent CHENE, Francesco STROZZI, Christophe BONNY, Alessandra CERVINO, Celia MENDEZ
  • Publication number: 20200062805
    Abstract: Protein kinase inhibitors and more specifically inhibitors of the protein kinase c-Jun amino terminal kinase are herein described. Additionally, JNK inhibitor sequences, chimeric peptides, nucleic acids encoding same as well as pharmaceutical compositions for treating pathophysiologies associated with JNK signaling are herein provided.
    Type: Application
    Filed: July 29, 2019
    Publication date: February 27, 2020
    Inventor: Christophe Bonny
  • Publication number: 20200025774
    Abstract: The present invention relates to cancer immunotherapy, in particular to sequence variants of tumor-related antigenic epitope sequences. Namely, the present invention provides a method for identification of microbiota sequence variants of tumor-related antigenic epitope sequences. Such microbiota sequence variants are useful for the preparation of anticancer medicaments, since they differ from self-antigens and, thus, they may elicit a strong immune response. Accordingly, medicaments comprising microbiota sequence variants, methods of preparing such medicaments and uses of such medicaments are provided.
    Type: Application
    Filed: October 9, 2017
    Publication date: January 23, 2020
    Applicant: ENTEROME S.A.
    Inventors: Laurent CHENE, Alessandra CERVINO, Francesco STROZZI, Celia MENDEZ, Christophe BONNY
  • Publication number: 20190337988
    Abstract: The present invention relates to novel transporter constructs of the generic formula (I) DlLLLxDm(LLLyDn)a and variants thereof. The present invention also refers to transporter cargo conjugate molecules, particularly of conjugates of the novel transporter constructs with a cargo moiety, e.g. proteins or peptides, nucleic acids, cytotoxic agents, organic molecules, etc. The present invention furthermore discloses (pharmaceutical) compositions comprising these conjugates and methods of treatment and uses involving such transporter constructs.
    Type: Application
    Filed: December 17, 2018
    Publication date: November 7, 2019
    Applicant: Xigen Inflammation Ltd.
    Inventor: Christophe Bonny
  • Patent number: 10174078
    Abstract: The present invention relates to isolated molecules, peptides, and polypeptides of specific consensus sequences or structures, and to compounds comprising or consisting of such molecules, peptides or polypeptides, that function as transporter moieties or compositions specifically recognizing the proteoglycan, keratan sulfate. The isolated molecules, peptides, polypeptides and compounds of the invention may be conjugated or otherwise linked to a biologically active moiety (BAM). Thus the BAM conjugates allow the specific targeting and delivery of the BAM, which may be, for example, a peptide, chemical entity or nucleic acid, into the cytoplasm and/or nuclei of keratan-sulfate expressing cells in vitro and in vivo.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: January 8, 2019
    Assignee: PHI PHARMA SA
    Inventors: Christophe Bonny, Fabrice Chenaux, Vincent Zoete
  • Patent number: 10131690
    Abstract: The present invention relates to isolated molecules, peptides, and polypeptides of specific consensus sequences or structures, and to compounds comprising or consisting of such molecules, peptides or polypeptides, that function as transporter moieties or compositions specifically recognizing the proteoglycan, chondroitin 6-sulfate (C6S). The isolated molecules, peptides, polypeptides and compounds of the invention may be conjugated or otherwise linked to a biologically active moiety (BAM). Thus the BAM conjugates allow the specific targeting and delivery of the BAM, which may be, for example, a peptide, chemical entity or nucleic acid, into the cytoplasm and/or nuclei of C6S expressing cells in vitro and in vivo.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: November 20, 2018
    Assignee: PHI PHARMA SA
    Inventors: Christophe Bonny, Fabrice Chenaux, Vincent Zoete
  • Patent number: 10023615
    Abstract: The present invention relates to the use of specific transporter cargo conjugate molecules for the transport of a substance of interest (cargo molecule) into white blood cells. Said transporter cargo conjugate molecules may be used for the treatment, prophylaxis, attenuation and/or amelioration of a disease and/or disorder involving white blood cells. The present invention also relates to manufacture of said transporter cargo conjugate molecules, to a method of transporting a substance of interest (cargo) into a white blood cell and to a white blood cell comprising said transporter cargo conjugate molecules or fragments thereof.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: July 17, 2018
    Assignee: Xigen Inflammation Ltd.
    Inventor: Christophe Bonny